Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.

Croyal M, Tran TT, Blanchard RH, Le Bail JC, Villard EF, Poirier B, Aguesse A, Billon-Crossouard S, Ramin-Mangata S, Blanchard V, Nativel B, Chemello K, Khantalin I, Thedrez A, Janiak P, Krempf M, Boixel C, Lambert G, Guillot E.

Clin Sci (Lond). 2018 May 31;132(10):1075-1083. doi: 10.1042/CS20180040. Print 2018 May 31.

PMID:
29724769
2.

The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

Lambert G, Thedrez A, Croyal M, Ramin-Mangata S, Couret D, Diotel N, Nobécourt-Dupuy E, Krempf M, LeBail JC, Poirier B, Blankenstein J, Villard EF, Guillot E.

Clin Sci (Lond). 2017 Feb 1;131(4):261-268. doi: 10.1042/CS20160403. Review.

PMID:
28108631
3.

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

Villard EF, Thedrez A, Blankenstein J, Croyal M, Tran TT, Poirier B, Le Bail JC, Illiano S, Nobécourt E, Krempf M, Blom DJ, Marais AD, Janiak P, Muslin AJ, Guillot E, Lambert G.

JACC Basic Transl Sci. 2016 Oct;1(6):419-427. doi: 10.1016/j.jacbts.2016.06.006.

4.

Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

El Khoury P, Ghislain M, Villard EF, Le Goff W, Lascoux-Combe C, Yeni P, Meyer L, Vigouroux C, Goujard C, Guerin M.

J Lipid Res. 2015 Mar;56(3):692-702. doi: 10.1194/jlr.M054510. Epub 2015 Jan 8.

5.

Adipocyte ATP-binding cassette G1 promotes triglyceride storage, fat mass growth, and human obesity.

Frisdal E, Le Lay S, Hooton H, Poupel L, Olivier M, Alili R, Plengpanich W, Villard EF, Gilibert S, Lhomme M, Superville A, Miftah-Alkhair L, Chapman MJ, Dallinga-Thie GM, Venteclef N, Poitou C, Tordjman J, Lesnik P, Kontush A, Huby T, Dugail I, Clement K, Guerin M, Le Goff W.

Diabetes. 2015 Mar;64(3):840-55. doi: 10.2337/db14-0245. Epub 2014 Sep 23.

6.

Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy.

Szalat R, Pirault J, Fermand JP, Carrié A, Saint-Charles F, Olivier M, Robillard P, Frisdal E, Villard EF, Cathébras P, Bruckert E, Chapman MJ, Giral P, Guerin M, Lesnik P, Le Goff W.

J Intern Med. 2014 Sep;276(3):269-84. doi: 10.1111/joim.12195. Epub 2014 Feb 10.

7.

Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels.

Villard EF, EI Khoury P, Frisdal E, Bruckert E, Clement K, Bonnefont-Rousselot D, Bittar R, Le Goff W, Guerin M.

Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):822-8. doi: 10.1161/ATVBAHA.112.300979. Epub 2013 Jan 31.

PMID:
23372063
8.

Endogenous CETP activity as a predictor of cardiovascular risk: determination of the optimal range.

Villard EF, Federspiel MC, Cherfils C, Fesel-Fouquier V, Bruckert E, Clement K, Bonnefont-Rousselot D, Le Goff W, Bittar R, Couvert P, Guerin M.

Atherosclerosis. 2013 Mar;227(1):165-71. doi: 10.1016/j.atherosclerosis.2012.12.024. Epub 2013 Jan 2.

PMID:
23312786
9.

Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women.

Villard EF, El Khoury P, Duchene E, Bonnefont-Rousselot D, Clement K, Bruckert E, Bittar R, Le Goff W, Guerin M.

Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2341-9. doi: 10.1161/ATVBAHA.112.252841. Epub 2012 Aug 16.

PMID:
22904275
10.

Human ATP-binding cassette G1 controls macrophage lipoprotein lipase bioavailability and promotes foam cell formation.

Olivier M, Tanck MW, Out R, Villard EF, Lammers B, Bouchareychas L, Frisdal E, Superville A, Van Berkel T, Kastelein JJ, Eck MV, Jukema JW, Chapman MJ, Dallinga-Thie GM, Guerin M, Le Goff W.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2223-31. doi: 10.1161/ATVBAHA.111.243519. Epub 2012 Jul 5. Erratum in: Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):e147.

PMID:
22772754
11.

Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia.

Orsoni A, Villard EF, Bruckert E, Robillard P, Carrie A, Bonnefont-Rousselot D, Chapman MJ, Dallinga-Thie GM, Le Goff W, Guerin M.

J Lipid Res. 2012 Apr;53(4):767-75. doi: 10.1194/jlr.M024141. Epub 2012 Feb 15.

12.

Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.

Bellanger N, Julia Z, Villard EF, El Khoury P, Duchene E, Chapman MJ, Fournier N, Le Goff W, Guerin M.

Atherosclerosis. 2012 Mar;221(1):160-8. doi: 10.1016/j.atherosclerosis.2011.12.027. Epub 2012 Jan 4.

PMID:
22265126

Supplemental Content

Loading ...
Support Center